Novavax to Start Phase III COVID-19 Trials in U.S. with Fast Track Designation

Novavax to Start Phase III COVID-19 Trials in U.S. with Fast Track Designation

Source: 
BioSpace
snippet: 

Maryland-based vaccine maker Novavax announced the big news that its COVID-19 vaccine candidate gained the U.S. Food and Drug Administration (FDA)’s “fast-track” status and is gearing up to begin its Phase III study in the U.S. later this month. Data from this study is expected to support U.S. authorization and approval for the company's vaccine.